MX367369B - Proceso para preparar inhibidores de la transcriptasa inversa. - Google Patents

Proceso para preparar inhibidores de la transcriptasa inversa.

Info

Publication number
MX367369B
MX367369B MX2016007303A MX2016007303A MX367369B MX 367369 B MX367369 B MX 367369B MX 2016007303 A MX2016007303 A MX 2016007303A MX 2016007303 A MX2016007303 A MX 2016007303A MX 367369 B MX367369 B MX 367369B
Authority
MX
Mexico
Prior art keywords
reverse transcriptase
transcriptase inhibitors
making reverse
hiv
making
Prior art date
Application number
MX2016007303A
Other languages
English (en)
Other versions
MX2016007303A (es
Inventor
David M Tschaen
Tetsuji Itoh
Gang Qian
Benjamin D Sherry
Cao Yang
R Jr Gauthier Donald
R Humphrey Guy
Journet Michel
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2016007303A publication Critical patent/MX2016007303A/es
Publication of MX367369B publication Critical patent/MX367369B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención está dirigida a un nuevo proceso para sintetizar derivados de 3-(fenoxi sustituido)-1-[(5-oxo-4,5-dihidr o-1H-1,2,4-triazol-3-iI)metiI])-piridin-2(1H-ona; los compuestos sintetizados por los procesos de la invención son inhibidores de la transcriptasa inversa del VIH útiles para inhibir la transcriptasa inversa y la replicación del VIH, y el tratamiento de la infección por el virus de la inmunodeficiencia humana en humanos.
MX2016007303A 2013-12-04 2014-12-02 Proceso para preparar inhibidores de la transcriptasa inversa. MX367369B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361911686P 2013-12-04 2013-12-04
US201462017542P 2014-06-26 2014-06-26
PCT/US2014/068008 WO2015084763A2 (en) 2013-12-04 2014-12-02 Process for making reverse transcriptase inhibitors

Publications (2)

Publication Number Publication Date
MX2016007303A MX2016007303A (es) 2016-08-04
MX367369B true MX367369B (es) 2019-08-16

Family

ID=53274271

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007303A MX367369B (es) 2013-12-04 2014-12-02 Proceso para preparar inhibidores de la transcriptasa inversa.

Country Status (10)

Country Link
US (1) US9598397B2 (es)
EP (2) EP3077376B1 (es)
JP (1) JP6244028B2 (es)
KR (1) KR101803671B1 (es)
CN (1) CN105793240B (es)
BR (1) BR112016012658B1 (es)
CA (1) CA2930585A1 (es)
ES (2) ES2977643T3 (es)
MX (1) MX367369B (es)
WO (1) WO2015084763A2 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711114D0 (en) * 1997-05-29 1997-07-23 Merck Sharp & Dohme Therapeutic agents
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
US7902240B2 (en) 2006-11-13 2011-03-08 Novartis Ag Substituted pyrazole and triazole compounds as KSP inhibitors
RU2010125220A (ru) * 2007-11-20 2011-12-27 Мерк Шарп Энд Домэ Корп. (Us) Ненуклеозидные ингибиторы обратной транскриптазы
EP2542077A4 (en) 2010-03-04 2013-08-21 Merck Sharp & Dohme CATECHOL O-METHYL TRANSFERASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PSYCHOTIC DISORDERS
PT2924034T (pt) * 2010-03-30 2017-01-06 Merck Canada Inc Composição farmacêutica compreendendo um inibidor de transcritase reversa não nucleosídico
WO2014052171A1 (en) 2012-09-26 2014-04-03 Merck Sharp & Dohme Corp. Crystalline form of a reverse transcriptase inhibitor
WO2014089140A1 (en) * 2012-12-05 2014-06-12 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors

Also Published As

Publication number Publication date
BR112016012658B1 (pt) 2022-06-21
MX2016007303A (es) 2016-08-04
EP3077376A2 (en) 2016-10-12
EP3617193A1 (en) 2020-03-04
CN105793240A (zh) 2016-07-20
CN105793240B (zh) 2018-05-18
BR112016012658A2 (es) 2017-08-08
US9598397B2 (en) 2017-03-21
ES2759976T3 (es) 2020-05-12
JP6244028B2 (ja) 2017-12-06
WO2015084763A3 (en) 2015-11-05
EP3077376B1 (en) 2019-10-16
JP2016540765A (ja) 2016-12-28
KR20160082695A (ko) 2016-07-08
WO2015084763A2 (en) 2015-06-11
EP3617193B1 (en) 2024-03-27
ES2977643T3 (es) 2024-08-28
EP3077376A4 (en) 2017-05-17
CA2930585A1 (en) 2015-06-11
US20160297794A1 (en) 2016-10-13
KR101803671B1 (ko) 2017-11-30

Similar Documents

Publication Publication Date Title
SA519402405B1 (ar) مركبات مثبط فيروس نقص المناعة البشري
PH12020550256A1 (en) 1-benzyl-2-imino-4-phenyl-5-oxoimidazolidine derivatives as hiv protease inhibitors
NZ585226A (en) Inhibitors of human immunodeficiency virus replication
EA201890200A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
MX2017007814A (es) Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico.
NZ598766A (en) Macrocyclic integrase inhibitors
TW201613885A (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
MY176210A (en) Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
MD4754B1 (ro) Compuşi policiclici de carbamoilpiridonă şi utilizarea lor farmaceutică
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
EA202190473A3 (ru) Противовирусная терапия
MX2012015097A (es) Derivados de acido naft-2-ilacetico para tratar sida.
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
AU2018253590A1 (en) Imidazopyridazine compounds
AU2016354007A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
PH12018501712A1 (en) Methods for treatment and prophylaxis of hiv and aids
MX355439B (es) Proceso para preparar inhibidores de la transcriptasa inversa.
TW201613939A (en) Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
MX367369B (es) Proceso para preparar inhibidores de la transcriptasa inversa.
IN2011CH03893A (es)
WO2016059647A3 (en) Triaminotriazine picolinonitrile derivatives as potent reverse transcriptase inhibitor of hiv-1
EA202092107A1 (ru) Производные циклизированного сульфамоилариламида и их применение в качестве лекарственных препаратов для лечения гепатита b

Legal Events

Date Code Title Description
FG Grant or registration